Westhampton Capital’s iShares Biotechnology ETF IBB Stock Holding History

Westhampton Capital’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,335	Closed	-$202K	–	110
2020 Q4	$202K	Buy	+1,335	New	+$191K	0.15%	99
2019 Q3	–	Sell	-4,115	Closed	-$449K	–	111
2019 Q2	$449K	Buy	+4,115	New	+$438K	0.38%	72

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Westhampton Capital's IBB Position: Q1 2021 in Review

Westhampton Capital sold out of iShares Biotechnology ETF (IBB) in Q1 2021, closing a stake of 1,335 shares — an estimated $202K sold.

Westhampton Capital first reported a position in IBB in Q2 2019 and held it in 2 quarters. The position peaked at $449K in Q2 2019. 845 funds tracked by Wall St. Rank hold IBB as of Q1 2021.

Westhampton Capital reported no remaining iShares Biotechnology ETF position as of Q1 2021 after selling out during the quarter.
Westhampton Capital sold 1,335 iShares Biotechnology ETF shares in Q1 2021, an estimated $202K.
Westhampton Capital first reported a position in iShares Biotechnology ETF in Q2 2019 and held it in 2 quarters.
Westhampton Capital's iShares Biotechnology ETF position peaked at $449K in Q2 2019.
845 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2021.

Based on Westhampton Capital's 13F filing for Q1 2021, filed 11 May 2021.